Levosalbutamol/ipratropium inhalation solution - Arrow International Limited/Sumitomo Pharma America
Alternative Names: Levalbuterol/ipratropium; Xopenex I.S. + ipratropium; Xopenex IS + ipratropium; Xopenex® + ipratropium inhalation solutionLatest Information Update: 22 Jul 2023
At a glance
- Originator Arrow International
- Class Antiasthmatics; Atropine derivatives; Bronchodilators; Ethanolamines; Phenethylamines
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 12 Oct 2010 Sepracor is now called Sunovion Pharmaceuticals
- 20 Oct 2009 Sepracor has been acquired by Dainippon Sumitomo Pharma
- 30 Apr 2008 Phase-II clinical trials in Chronic obstructive pulmonary disease in Europe (Inhalation)